

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC

Form 8-K

October 26, 2001

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
October 26, 2001 (October 26, 2001)

BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)

| | | |
|---|--|--|
| Delaware (State or other jurisdiction of incorporation) | 000-26727 (Commission File Number) | 68-0397820 (IRS Employer Identification No.) |
|---|--|--|

| | |
|--|---------------------|
| 371 Bel Marin Keys Boulevard, Suite 210 Novato, California (Address of principal executive offices) | 94949 (Zip Code) |
|--|---------------------|

(415) 884-6700
(Registrant's telephone number, including area code)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

Item 5. Other Events

On October 26, 2001, we announced our financial results for the quarter ended September 30, 2001 in a press release, dated October 26, 2001. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Financial Statements and Exhibits

EXHIBIT NO. DESCRIPTION OF DOCUMENT

99.1 Press Release Dated October 26, 2001 related to announcement of third quarter 2001 financial results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.

By: /s/ Raymond W. Anderson

Raymond W. Anderson
Chief Operating Officer, Chief Financial
Officer, Secretary and Vice President
Finance and Administration

Date: October 26, 2001

Exhibit Index

EXHIBIT NO. DESCRIPTION OF DOCUMENT

99.1 Press Release Dated October 26, 2001 related to announcement of third quarter 2001 financial results.